Accéder au contenu
Merck
Toutes les photos(1)

Documents

N-004

Supelco

Naloxone solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C19H21NO4
Numéro CAS:
465-65-6
Poids moléculaire :
327.37
Numéro CE :
200-659-6
Numéro MDL:
MFCD00242634
Code UNSPSC :
41116107
ID de substance PubChem :
329818392
Nomenclature NACRES :
NA.24

Qualité

certified reference material

Niveau de qualité

300

Forme

liquid

Caractéristiques

Snap-N-Spike®/Snap-N-Shoot®

Conditionnement

ampule of 1 mL

Fabricant/nom de marque

Cerilliant®

Concentration

1.0 mg/mL in methanol

Technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Application(s)

forensics and toxicology

Format

single component solution

Température de stockage

2-8°C

Chaîne SMILES 

Oc1ccc2C[C@H]3N(CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O)CC=C

InChI

1S/C19H21NO4/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11/h2-4,14,17,21,23H,1,5-10H2/t14-,17+,18+,19-/m1/s1

Clé InChI

UZHSEJADLWPNLE-GRGSLBFTSA-N

Informations sur le gène

human ... OPRD1(4985) , OPRK1(4986) , OPRM1(4988)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

Naloxone is an opiate drug used to counter the effects of opioid overdose. This certified solution standard is applicable for use in LC/MS or GC/MS applications such as clinical toxicology and forensic analysis. Naloxone is sold under the trade names Narcan®, Nalone, and Narcan®ti.

Informations légales

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Narcan is a registered trademark of Endo Pharmaceuticals Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

P-071

Pain Management Multi-component Opiate Mixture-13 solution, 100 μg/mL each component (10 μg/mL Fentanyl), ampule of 1.0 mL, certified reference material, Cerilliant®

IMPN-007-04

Naloxone N-oxide solution, 100 μg/mL in acetonitrile: water (1:1), ampule of 1 mL, certified reference material, Cerilliant®

N-063

Naloxone-D5 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

N-924

Nalorphine hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

N-115

Naloxone-D5 solution, 1.0 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

N-004S

Naloxone solution, 1 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

Pictogrammes

FlameSkull and crossbonesHealth hazard
GHS02,GHS06,GHS08

Mention d'avertissement

Danger

Classification des risques

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Organes cibles

Eyes,Central nervous system

Code de la classe de stockage

3 - Flammable liquids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

49.5 °F - closed cup

Point d'éclair (°C)

9.7 °C - closed cup

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

R Terry Furst
Journal of addictive diseases, 32(1), 53-67 (2013-03-14)
This study explores strategies that Suboxone misusers utilize while in drug treatment. Ethnographic interviews were conducted with 14 patients who had cycled in and out of Suboxone treatment. The objective of the study is to identify strategies implemented by patients
Anne M Neumann et al.
Journal of addictive diseases, 32(1), 68-78 (2013-03-14)
Patients with opioid addiction who receive prescription opioids for treatment of nonmalignant chronic pain present a therapeutic challenge. Fifty-four participants with chronic pain and opioid addiction were randomized to receive methadone or buprenorphine/naloxone. At the 6-month follow-up examination, 26 (48.1%)
Robert Taylor et al.
Expert opinion on investigational drugs, 22(4), 517-525 (2013-03-15)
Opioid receptor antagonists are well known for their ability to attenuate or reverse the effects of opioid agonists. This property has made them useful in mitigating opioid side effects, overdose and abuse. Paradoxically, opioid antagonists have been reported to produce
Liang-Wu Fu et al.
American journal of physiology. Heart and circulatory physiology, 305(1), H76-H85 (2013-05-07)
Thinly myelinated Aδ-fiber and unmyelinated C-fiber cardiac sympathetic (spinal) sensory nerve fibers are activated during myocardial ischemia to transmit the sensation of angina pectoris. Although recent observations showed that myocardial ischemia increases the concentrations of opioid peptides and that the
The opioid system is involved in the analgesic effects of Tactivin.
A N Inozemtsev et al.
Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections, 450, 130-133 (2013-07-04)
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique